+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID04526431

Study of Tacrolimus Metabolism and Its Impact on Kidney Transplant Outcomes Comparing Once-Daily vs Twice-Daily Tacrolimus Treatment Over Four Years After Transplantation

Led by University Hospital, Grenoble · Updated on 2021-02-10

180

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating how the body processes tacrolimus, a key immunosuppressive drug used after kidney transplantation. This study focuses on understanding differences in tacrolimus metabolism by measuring specific metabolites and analyzing genetic factors. The goal is to explain why some patients, identified by a lower concentration-to-dose ratio, may have different kidney transplant survival outcomes compared to others. Participants will be randomly assigned to receive tacrolimus either as a once-daily prolonged-release form or as a twice-daily immediate-release form. The study will follow these patients for four years after their kidney transplant. During this time, regular visits will include biological tests, adherence questionnaires, kidney biopsies at specific months, and pharmacokinetic studies to monitor tacrolimus exposure. Throughout the study, participants will undergo consultations at 6 weeks, 3, 6, 12, 24, 36, and 48 months post-transplant. Evaluations include blood tests, genetic analysis at enrollment, and measuring tacrolimus metabolite and residual concentrations at 3 months. Researchers will assess how metabolism differences relate to kidney transplant outcomes while monitoring patient safety and treatment adherence over the four-year period.

CONDITIONS

Brief Title

Tacrolimus Pharmacokinetic Subpopulations

Research Team

T

Thomas JOUVE, MD, PhD

J

Johan NOBLE, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here